{"a":[{"_":"No patent protection for Stelara? No problem for J&J as Tremfya fills the void","$":{"href":"/pharma/no-patent-protection-stelara-no-problem-jj-tremfya-fills-void","hreflang":"en"}}]}

Summary

Johnson & Johnson reported its fifth consecutive quarter with at least 6% revenue growth, with Tremfya exceeding $2 billion in quarterly sales for the first time despite Stelara losing patent protection.